Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy
for stage III melanoma: outcome prediction in a multicenter trial.
with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent.
Last week, Hees went to the John Wayne Cancer Institute in Santa Monica for five days of biochemotherapy
ORLANDO, Florida, May 17 /PRNewswire-FirstCall/ -- Adding a novel maintenance biotherapy regimen to biochemotherapy protocols may significantly improve time-to-disease progression and overall survival in metastatic melanoma patients, according to new data presented at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Because higher response rates have not translated to improved survival in multi-center randomized trials of biochemotherapy in metastatic melanoma, we wanted to see if we could repeat single-institution pilot data that suggested improved survival for patients receiving maintenance biotherapy following induction biochemotherapy," said lead study investigator Steven O'Day, M.
These data are from a multi-center Phase II study, involving a total of 133 patients at 10 high-volume melanoma centers in the United States, developed in an effort to improve durability of systemic responses following induction biochemotherapy in metastatic melanoma patients.
John's Health Center in Santa Monica, California, after having undergone a 3 1/2-month long, highly-aggressive, biochemotherapy treatment.
It was decided to radiate those sites as well and, upon completion of radiation, Reagan returned to The John Wayne Cancer Institute for resumption of the biochemotherapy.
Reagan was taken by air ambulance to The John Wayne Cancer Institute in Santa Monica, California, where on December 16 she began her first biochemotherapy treatments.
Reagan should immediately undertake an aggressive biochemotherapy regimen at the most experienced facility in California, the John Wayne Cancer Institute in Santa Monica, California.
Reagan was admitted to the John Wayne Cancer Institute at Saint John's Health Center on December 11, 2000, and began an aggressive biochemotherapy treatment on December 16, 2000.
have provided varying tumor responses